[HTML][HTML] Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient …
DP Steensma, MR Baer, JL Slack… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2009•ncbi.nlm.nih.gov
Purpose Decitabine, a DNA-targeted hypomethylating agent, is approved by the United
States Food and Drug Administration for treatment of patients with myelodysplastic
syndromes (MDS) on a schedule of 15 mg/m 2 administered via intravenous (IV) infusion
every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing
regimen administered on an outpatient basis in academic and community-based practices.
States Food and Drug Administration for treatment of patients with myelodysplastic
syndromes (MDS) on a schedule of 15 mg/m 2 administered via intravenous (IV) infusion
every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing
regimen administered on an outpatient basis in academic and community-based practices.
Abstract
Purpose
Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m 2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices.
ncbi.nlm.nih.gov